Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial

Read, Jane; Beale, Philip; Völker, D; Smith, Narelle; Childs, Annabel; Clarke, Stephen

doi:10.1007/s00520-006-0153-3

Cited by 115 publications

(117 citation statements)

References 27 publications

(27 reference statements)

Supporting

Mentioning

105

Contrasting

Unclassified

Order By: Relevance

“…It has been reported that nutritional management is important in HOI treatment (7,8). Recent studies have reported that ProSure™ (Abbot Japan Co., Ltd, Tokyo, Japan), an EPA-containing supplement, affects the nutritional status and quality of life in advanced cancer patients (17,18). ProSure™ was introduced in postoperative nutritional management and the ileostomy output was examined.…”

Section: Discussionmentioning

confidence: 99%

Prediction model and treatment of high-output ileostomy in colorectal cancer surgery

Fujino

Miyoshi

Ohue

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The aim of the present study was to examine the risk factors of high-output ileostomy (HOI), which is associated with electrolyte abnormalities and/or stoma complications, and to create a prediction model. The medical records of 68 patients who underwent colorectal cancer surgery with ileostomy between 2011 and 2016 were retrospectively investigated. All the patients underwent surgical resection for colorectal cancer at the Osaka Medical Center for Cancer and Cardiovascular Diseases (Osaka, Japan). A total of 7 patients with inadequate data on ileostomy output were excluded. Using a group of 50 patients who underwent surgery between 2011 and 2013, the risk of HOI was classified by a decision tree model using a partition platform. The HOI prediction model was validated in an additional group of 11 patients who underwent surgery between 2014 and 2016. Univariate analysis of clinical factors demonstrated that young age (P=0.003) and high white blood cell (WBC) count (P<0.001) after surgery were significantly correlated with HOI. Operative factors, such as surgical procedure, approach, operative time and blood loss, were not significantly correlated with HOI. Using these clinical factors, the risk of HOI was classified by statistical partition. In this model, three factors (gender, age and WBC on postoperative day 1) were generated for the prediction of HOI. The patients were classified into five groups, and HOI was observed in 0-88% of patients in each group. The area under the curve (AUC) was 0.838. The model was validated by an external dataset in an independent patient group, for which the AUC was 0.792. In conclusion, HOI patients were classified and an HOI prediction model was developed that may help clinicians in postoperative care. IntroductionSurgery is an effective treatment for colorectal cancer (CRC) (1,2), and certain procedures, such as low anterior resection and intersphincteric resection for lower rectal cancer, require an ileostomy to reduce the risk of severe anastomotic leakage (3-5). High-output ileostomy (HOI) is often observed and is accompanied by electrolyte abnormalities and/or stoma complications (6-8).The aim of the present study was to determine the frequency and risk factors of HOI and to create a prediction model of HOI. Predicting HOI may be useful for perioperative treatment. Patients and methodsPatients and data sets. A total of 68 consecutive patients who underwent surgery for colorectal cancer with ileostomy at the Osaka Medical Center for Cancer and Cardiovascular Diseases (Osaka, Japan) between 2011 and 2016 were retrospectively analyzed. HOI was defined by a maximum output of >2,000 ml/day and high output (>1,000 ml/day) lasting for >3 days (Fig. 1). A total of 7 patients for whom detailed data of output were unavailable were excluded (Fig. 2). Based on a group of 50 patients who underwent surgery between 2011 and 2013, a decision tree was used to develop a prediction model for HOI. Clinicopathological factors, such as patient sex, age, body mass index, tumor stage, pr...

show abstract

Section: Discussionmentioning

confidence: 99%

Prediction model and treatment of high-output ileostomy in colorectal cancer surgery

Fujino

Miyoshi

Ohue

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…(42). Read et al (43) indicated that after an average amount of 408 ml/day EPA for 3 weeks, a significant increase was noted in mean patient weight (2.5 kg) (p=0.03), and LBM was maintained. In the summary of this study, it was stated that dietary counseling by suitably qualified dietitians and the administration of EPA in patients with advanced colerectal cancers receiving chemotherapy, help to maintain weight and possibly improve symptom control, nutritional status and QoL.…”

Section: Drug Treatmentmentioning

confidence: 99%

New perspective for nutritional support of cancer patients: Enteral/parenteral nutrition

Akbulut

2011

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

“…48 According to a recent systematic review, malnourished cancer patients, receiving nutritional counseling along with or without ONS resulted in nutritional status improvements. 49 Body weight increase in cancer patients consuming ONS leads to maintenance of lean body mass and better quality of life 50 . Better nutritional status among head and neck as well as gastrointestinal tract cancer patients consuming ONS compared to patients receiving standard care has been reported earlier.…”

Section: Nutrition Intervention and Its Benefitsmentioning

confidence: 99%

Palliative Nutritional Care for Cancer Patients

Kapoor¹,

Garg²,

Tewfik³

2016

Palliat Med Hosp Care Open J

View full text Add to dashboard Cite

Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial

Abstract: Dietary counseling and the provision of EPA-ONS may result in maintenance of nutritional status and QOL, however randomized trials are required to evaluate the impact of EPA on toxicity from chemotherapy.

Cited by 115 publications

References 27 publications

Prediction model and treatment of high-output ileostomy in colorectal cancer surgery

Prediction model and treatment of high-output ileostomy in colorectal cancer surgery

New perspective for nutritional support of cancer patients: Enteral/parenteral nutrition

Palliative Nutritional Care for Cancer Patients

Contact Info

Product

Resources

About